Eligard receives marketing authorisation in Germany
Atrix Laboratories has received marketing authorisation in Germany for its one-month prostate cancer product, Eligard 7.5mg (leuprolide acetate) for injectable suspension, known as Leuprogel, through its European licensee MediGene.
Atrix Laboratories has received marketing authorisation in Germany for its one-month prostate cancer product, Eligard 7.5mg (leuprolide acetate) for injectable suspension, known as Leuprogel, through its European licensee MediGene.
Leuprolide acetate is a lutenizing hormone releasing hormone (LHRH) agonist. Sustained levels of leuprolide acetate decrease testosterone levels to suppress tumour growth in patients with hormone-responsive prostate cancer. 'Germany is the largest market for LHRH therapies in Europe, so gaining German approval is a major advancement in globalising this product,' said David R. Bethune, Atrix's chairman and ceo.
Approvals in other European countries are expected as part of the mutual recognition process.